Our data have now showed that serglycin is highly expressed by aggressive MDA-MB-231 breast cancer cells, which belong to the Basal B subgroup, and they show mesenchymal phenotype, enhanced invasive properties and enriched expression of EMT transcriptional drivers [21]. Here, SRGN is linked to breast cancer.